No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 3 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for YD Bio Limited Ordinary Shares (YDES) stock was $6.13 as of Oct 6, 2026, 3:55 PM EDT, down 13.76% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -61.6%
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan.
Biotechnology · Taipei, TP
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1YDES | $434.30M | $6.13 | -13.76% | -61.60% | N/A | N/A | N/A |
| 2DMAC | $434.84M | $8.07 | -4.16% | +19.00% | +16.41% | +7.89% | vs YDES |
| 3NPCE | $435.38M | $12.77 | -3.40% | +20.95% | -4.94% | N/A | vs YDES |
| 4ASMB | $439.45M | $22.18 | -2.48% | -2.48% | -10.66% | -13.41% | vs YDES |
| 5NEO | $425.64M | $16.57 | -13.41% | +109.48% | -15.14% | +8.90% | vs YDES |
| 6SPRY | $425.51M | $4.29 | -0.12% | -58.22% | -16.35% | N/A | vs YDES |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$6.13
High
N/A
